Categories: DevelopmentDrugSpecialty
Investors 1
Funding Rounds 1
| Date | Series | Amount | Investors |
| 21.07.2015 | Series A | $12M | - |
Mentions in press and media 5
| Date | Title | Description |
| 17.02.2017 | Term Sheet — Friday, February 17 | IT’s TIME TO TAKE AI SERIOUSLY
The following is from the latest print edition of Fortune, where I write a regular column about technology and startups called “💥Boom with a View💥.”
Paid Content You can't secure what you can't see From ExtraH... |
| 26.08.2016 | Sofinnova Ventures has raised $595M for its largest fund to date | The company’s strategy of investing in late-stage private companies has found some receptive buyers for those businesses, demonstrated by acquisitions of its portfolio companies from the likes of Teva, Shire and Pfizer.
And yet, it has also... |
| 21.07.2015 | Dauntless Pharmaceuticals Closes $12M Series A Financing | Dauntless Pharmaceuticals, Inc., a San Diego, CA-based biopharmaceutical company focused on the development of specialty drugs, closed a $12m Series A financing.
Sofinnova Ventures was the sole institutional investor in the Series A financi... |
| 21.07.2015 | Daily funding roundup - July 21, 2015 | Bright.md raises $3.5M; Medallia bagged $150M; BrightBytes landed $33M
Bright.md, which makes software that enables communication between doctors and patients, closed a $3.5 million Series A funding round. Oregon Angel Fund led the round, w... |
| - | Sofinnova Ventures has raised $595M for its largest fund to date | Life sciences investor Sofinnova Ventures is raising fund number 10 in what, as FierceBiotech notes, appears to be its largest fund to date. A previous fund, dating back to 2014, raised $500 million.
The investment firm did not immediately ... |
Reviews 0
